Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.6 USD | -4.28% | -11.21% | -26.29% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.29% | 228M | |
+10.22% | 226B | |
+12.99% | 198B | |
+18.09% | 142B | |
+28.66% | 111B | |
+2.09% | 65.26B | |
+14.70% | 54.36B | |
+6.68% | 50.94B | |
+8.29% | 44.8B | |
+2.60% | 36.8B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating